Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

17.95
+0.64003.70%
Pre-market: 17.66-0.2897-1.61%05:14 EDT
Volume:8.18M
Turnover:146.27M
Market Cap:14.32B
PE:-16.06
High:18.33
Open:17.10
Low:16.98
Close:17.31
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:154.32M
Volume Ratio:1.10
T/O Rate:5.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:22.73
PE(LYR):-12.43

Loading ...

Movement Alert|Summit Therapeutics PLC Intraday Rise 5.23%, AstraZeneca $2B Investment and Combination Therapy Collaboration Boost Shares

Market Focus
·
Yesterday

Movement Alert|Summit Therapeutics PLC Rises 5.1% in Regular Trading, AstraZeneca Closes $2 Billion Investment

Market Focus
·
Oct 06

AstraZeneca completes $2B equity investment in Summit Therapeutics

TIPRANKS
·
Oct 05

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

THOMSON REUTERS
·
Oct 05

Kia Ranks Second in UK Sales for First Eight Months of the Year, Trailing Only Volkswagen

Deep News
·
Oct 05

Summit Therapeutics (SMMT) Teams Up With AstraZeneca And Daiichi Sankyo, Is It 43% Undervalued?

Simply Wall St.
·
Oct 04

Sector Update: Healthcare

MT Newswires Live
·
Oct 03

Deals of the Day-Mergers and Acquisitions

Reuters
·
Oct 02

Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo

TIPRANKS
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

AstraZeneca & Daiichi Sankyo Announce Clinical Collaboration with Summit Therapeutics

Reuters
·
Oct 02

Summit Therapeutics Partners with AstraZeneca, Daiichi Sankyo to Test Ivonescimab with Datroway in Solid Tumors

Reuters
·
Oct 02

AstraZeneca - Co, Daiichi Sankyo, Summit to Contribute to Trial Costs and Retain Rights

THOMSON REUTERS
·
Oct 02

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with Trop2-Directed ADC Datroway

THOMSON REUTERS
·
Oct 02

Summit Therapeutics is Maintained at Equal-Weight by Barclays

Dow Jones
·
Oct 01

Summit Therapeutics Inc. : Barclays Raises Target Price to $20 from $18

THOMSON REUTERS
·
Oct 01

Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), Summit Therapeutics (SMMT) and Sutro Biopharma (STRO)

TIPRANKS
·
Oct 01

Movement Alert|Summit Therapeutics PLC Rises 5.03% in Regular Trading, AstraZeneca $2 Billion Investment Continues to Boost Sentiment

Market Focus
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

AstraZeneca Hedges Threat to Oncology Portfolio

Dow Jones
·
Sep 30